DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update

-         FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

-         Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design

Read more at prnewswire.com